General Information of DTT (ID: TTNCIE0)

DTT Name CD70 antigen (CD27-L) DTT Info
Gene Name CD70

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
11 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
JNJ-74494550 DM3ICO6 Myelodysplastic syndrome 2A37 Phase 2 [1]
4SCAR19 and 4SCAR70 DMKC8F9 B-cell lymphoma 2A86 Phase 1/2 [2]
AMG 172 DMS72GN Renal cell carcinoma 2C90 Phase 1 [3]
Anti-hCD70 CAR transduced PBL DMK4GIS Ovarian cancer 2C73 Phase 1 [4]
BMS-936561 DMYIBFM Haematological malignancy 2B33.Y Phase 1 [5]
CTX130 DM926CH T-cell lymphoma 2A90 Phase 1 [6]
MDX-1203 DM0RIQF Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
MDX-1411 DM3402P Solid tumour/cancer 2A00-2F9Z Phase 1 [8]
SEA-CD70 DMX94YF Acute myeloid leukaemia 2A60 Phase 1 [9]
SGN-70 DMXA7W9 Autoimmune diabetes 5A10 Phase 1 [10]
SGN-CD70A DMMJ1PO Non-hodgkin lymphoma 2B33.5 Phase 1 [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 Clinical Trial Drug(s)
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorsetuzumab mafodotin DMATEL0 Renal cell carcinoma 2C90 Discontinued in Phase 1 [12]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
TriMixDC DML3OYH Melanoma 2C30 Investigative [13]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
2 ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
3 National Cancer Institute Drug Dictionary (drug id 721679).
4 ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
5 Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
6 Clinical pipeline report, company report or official report of CRISPR Therapeutics.
7 J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
8 Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
9 Clinical pipeline report, company report or official report of Seagen.
10 2011 Pipeline of Seattle Genetics.
11 SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.
12 National Cancer Institute Drug Dictionary (drug id 660730).
13 Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.